

Members Obtain Free CE Credits from JCP Articles!



Pharmacokinetics of Ganaplacide and Lumefantrine in Adults, Adolescents, and Children with Plasmodium falciparum Malaria Treated with Ganaplacide Plus Lumefantrine Solid Dispersion Formulation: Analysis of Data from a Multinational Phase 2 Study

February 2025 – *The Journal of Clinical Pharmacology* (JCP)

Why is this article important to you?

This activity will expand learner knowledge related to the safe and efficacious dosing of a novel antimalarial ganaplacide in combination with lumefantrine. This will aid in understanding the pharmacokinetic data and process that indicate the exposures of ganaplacide and lumefantrine that were safe and needed for efficacy. Learners that complete this course will learn how antimalaria combination ganaplacide and lumefantrine dose regimen was tested and selected.



ACPE Accreditation Statement

The American College of Clinical Pharmacology® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

UAN: 0665-0000-25-002-H01-P – ACPE 1 Contact Hours

Activity Type: Knowledge-based **Format:** Home-study **Target Audience:** 'P'



ACCME
ACCREDITED

ACCME Accreditation Statement

The American College of Clinical Pharmacology® is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

ACCME Designation Statement

The Accreditation Council for Continuing Medical Education designates this journal CE activity for 1 *AMA PRA Category 1™* credit. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Target Audience

Interprofessional team of Physicians, Pharmacists, PhDs, Pediatricians and Nurses interested in expanding their knowledge on the antimalaria combination ganaplacide and lumefantrine dosing regimen.

Learning Objectives

After completing this activity, the learner will be able to:

1. Describe the potential pharmacokinetic interaction between ganaplacide and lumefantrine when coadministered;
2. Identify how effective and well-tolerated six treatment regimens are in adult/adolescent patients;
3. Explain the efficacy, tolerability and safety in children aged 2 to <12 years with body weight ≥ 10 kg.

Requirements to Receive Credit

In order to receive continuing medical education (CME) or continuing pharmacy education (CPE) credit, the learner must register for the educational activity, study the provided journal article, complete the online learning Self-assessment Post-test as well as the online course Evaluation and CME/CPE Certificate. Credits and CME/CPE Certificates must be claimed within thirty (30) days of completing the article, Post-test and Evaluation. Contact CE@ACCP1.org with any questions.

Disclosures:

Article Selection: John van den Anker, MD, PhD, Editor-in-Chief, JCP, selected the article for this course and has nothing to disclose.

Planner: Kenneth Der, BS, Associate Director, Amgen Inc, planned the continuing education documentation for this course and all of the relevant financial relationships listed for this individual have been mitigated.

CE Reviewer: Kannan Sridharan, MBBS, MD, DM, FCS, Professor, Arabian Gulf Univ, served as the CE Reviewer and has nothing to disclose.

Schedule & Fees

JCP monthly Journal CE articles are generally released on the 1st or 2nd Tuesday of each month. They are priced in packages of January to December for each year. Packages are available at no cost to ACCP Members and \$75/calendar year to Non-members. Once you register, you have access to all of the Journal CE articles for the calendar year.

Acknowledgement of Financial Support

No financial support was received for this educational activity.

Home Study Initial Release and Expiration Dates

Date of Issuance: 2/1/2025

Expiration Date: 2/1/2028

Online Location:

https://accp1.org/Members/ACCP1/4Continuing_Education/Journal_CE.aspx?hkey=aDecf2ad-e111-4e26-92b5-bbd8ce8fda14